Audentes Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$212.5M
Industry:Biotech
Founded:2013
Lead Investor(s):BofA Merrill Lynch, J.P. Morgan Securities LLC
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Audentes Therapeutics's revenue is currently $26.7M per year.
  • Audentes Therapeutics received $172.5M in venture funding in October 2018.
  • Audentes Therapeutics's revenue per employee is $121735
  • Audentes Therapeutics's total funding is $212.5M.

Employee Data

  • Audentes Therapeutics has 219 Employees.
  • Audentes Therapeutics grew their employee count by 27% last year.
  • Audentes Therapeutics currently has 28 job openings.

What Is Audentes Therapeutics?

Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities. If you are interested in learning more about our company, please do not hesitate to contact us.

keywords:Biotechnology,Healthcare,Pharmaceuticals

219

Number of Employees

$26.7M

Revenue (est)

28

Current Jobs

27%

Employee Growth %

$212.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
$7.4M6944%
Rigel Pharmaceu...
$40.5M2714%
ProTrials Resea...
$25.6M1703%
Advanced Cell D...
$23.9M1668%
CellMax Life
$10M379%$9M
Atreca
$10.7M8117%
Full Spectrum A...
$5.7M395%
Pipette.com/Acc...
N/AN/A
Irvine Scientif...
$29.1M2059%
Talis Biomedica...
$8.1M544%

Audentes Therapeutics News

20-Mar-19 - Analysts Offer Insights on Healthcare Companies: Audentes

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (BOLD – Research Report)

20-Mar-19 - Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating

Today, HC Wainwright reiterated its Buy rating on Audentes Therapeutics Inc (NASDAQ:BOLD) with a price target of $44.00. There are 7 Buy

7-Mar-19 - Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You

As such, the Zacks rating upgrade for Audentes Therapeutics is essentially a positive comment on its earnings outlook that could have a

Audentes Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-07-22$30.0MAOrbiMed Advisors, 5AM VenturesArticle
2014-12-03$42.5MBDeerfield ManagementArticle
2015-10-14$65.0MCSofinnova VenturesArticle
2017-04-20$75.4MUndisclosedMultipleArticle
2018-01-24$172.5MUndisclosedBofA Merrill LynchArticle
2018-01-26$231.4MUndisclosedBofA Merrill LynchArticle
2018-10-10$172.5MUndisclosedBofA Merrill LynchArticle

Audentes Therapeutics Executive Hires

DateNameTitleReference
2014-03-05Suyash PrasadSVP/Chief Medical OfficerArticle
2015-09-30Natalie HollesSVP/COOArticle
2017-05-09John GraySVP/Chief Scientific OfficerArticle
2017-07-19Fulvio MavilioVP scientific affairs, EuropeArticle
2018-05-09Natalie HollesPresident/Chief Operating OfficerArticle
2018-11-06Matthew PattersonChairmanArticle
2019-01-04Eric MosbrookerSVP/Chief Commercial OfficerArticle